PORTEFEUILLE

UNOMR, a techBio startup from ETH Zürich is pioneering single-molecule protein modification analysis through their innovative dynamic nanopore sensor. The current focus lies on the site-specific analysis of protein modifications with sugars, called glycosylation, which are aberrant in autoimmune diseases or epithelial tumors associated with breast or pancreatic cancer. Their patented solution has far-reaching applications across healthcare, pharmaceutical development, and food science, offering a powerful new tool for therapeutic discoveries and medical food innovation. Driven by the vision of bringing advanced proteomics directly to the patient, UNOMR aims to catalyze the next breakthrough in precision medicine by making sophisticated protein analysis accessible.

Goal of the project is to bring an existing prototype closer to an MVP. The sensor consists of two parts: 1) sensor hardware and 2) consumables based on silicon chips which need to be replaced regularly. Within the project the focus lies on the scale-up and improved reliability of the consumables. The design and casing of the silicon chip will be improved in the first half of the project.
We have a partnership with Nestlé to test the potential of single-protein glycosylation occupancy with our technology. Beyond the on-going project our focus is to show pharma and biotech industry the benefits of single-molecule proteomics and how it can help to solve some of their most urgent challenges these industry face.